Engagement with the patient community to accelerate new therapies

At True North, we are driven by our desire to understand and meet the needs of patients in the challenging area of rare diseases driven by the Complement system. This is demonstrated by our commitment to invest our scientific and clinical resources to treat these underserved patient populations. We also work with research collaborators and clinical advisors to better understand the natural history of the disease and develop clinical biomarkers. This integrated approach works toward one goal—to advance and accelerate development of effective therapies for these rare diseases.